{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:10:30Z","timestamp":1785298230375,"version":"3.55.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Chilean Fondecyt","award":["1110260"],"award-info":[{"award-number":["1110260"]}]},{"name":"Chilean Fondecyt","award":["1130561"],"award-info":[{"award-number":["1130561"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.vaccine.2017.06.043","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T17:00:29Z","timestamp":1498669229000},"page":"5435-5441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Norovirus vaccines under development"],"prefix":"10.1016","volume":"36","author":[{"given":"Yalda","family":"Lucero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"O'Ryan G","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.06.043_b0005","unstructured":"International committee on taxonomy of viruses. Virus taxonomy: 2014 release; 2015 [Internet]. Available from: https:\/\/talk.ictvonline.org\/ictv-reports\/ictv_9th_report\/positive-sense-rna-viruses-2011\/w\/posrna_viruses\/253\/caliciviridae [cited 2017 Jan 20]."},{"issue":"5 Pt 2","key":"10.1016\/j.vaccine.2017.06.043_b0010","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2460\/javma.1978.173.05.615","article-title":"Norwalk agent-like particles associated with gastroenteritis in human beings","volume":"173","author":"Dolin","year":"1978","journal-title":"J Am Vet Med Assoc"},{"issue":"5","key":"10.1016\/j.vaccine.2017.06.043_b0015","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1128\/JVI.10.5.1075-1081.1972","article-title":"Visualization by immune electron microscopy of a 27-nm particle associated with acute infectious nonbacterial gastroenteritis","volume":"10","author":"Kapikian","year":"1972","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2017.06.043_b0020","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1128\/iai.29.2.822-823.1980","article-title":"Comparative study of the acquisition of antibody to Norwalk virus in pediatric populations","volume":"29","author":"Cukor","year":"1980","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2017.06.043_b0025","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1086\/315874","article-title":"Human caliciviruses are a significant pathogen of acute sporadic diarrhea in children of Santiago, Chile","volume":"182","author":"O\u2019Ryan","year":"2000","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2017.06.043_b0030","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/infdis\/139.5.564","article-title":"Role of Norwalk virus in outbreaks of nonbacterial gastroenteritis","volume":"139","author":"Greenberg","year":"1979","journal-title":"J Infect Dis"},{"issue":"4987","key":"10.1016\/j.vaccine.2017.06.043_b0035","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1126\/science.2177224","article-title":"Norwalk virus genome cloning and characterization","volume":"250","author":"Xi","year":"1990","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.vaccine.2017.06.043_b0040","doi-asserted-by":"crossref","first-page":"6527","DOI":"10.1128\/JVI.66.11.6527-6532.1992","article-title":"Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein","volume":"66","author":"Jiang","year":"1992","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2017.06.043_b0045","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.gtc.2006.03.001","article-title":"The epidemiologic and clinical importance of norovirus infection","volume":"35","author":"Atmar","year":"2006","journal-title":"Gastroenterol Clin North Am."},{"issue":"7","key":"10.1016\/j.vaccine.2017.06.043_b0050","doi-asserted-by":"crossref","first-page":"e41619","DOI":"10.1371\/journal.pone.0041619","article-title":"The effects of simvastatin or interferon-\u03b1 on infectivity of human norovirus using a gnotobiotic pig model for the study of antivirals","volume":"7","author":"Jung","year":"2012","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.vaccine.2017.06.043_b0055","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00450-13","article-title":"A mouse model for human norovirus","volume":"4","author":"Taube","year":"2013","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2017.06.043_b0060","doi-asserted-by":"crossref","unstructured":"Havelaar AH, Kirk MD, Torgerson PR, Gibb HJ, Hald T, Lake RJ, et al. World Health Organization global estimates and regional comparisons of the burden of foodborne disease in 2010. PLOS Med 2015;12(12):e1001923 [von Seidlein L, editor].","DOI":"10.1371\/journal.pmed.1001923"},{"issue":"9888","key":"10.1016\/j.vaccine.2017.06.043_b0065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","article-title":"Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study","volume":"382","author":"Kotloff","year":"2013","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2017.06.043_b0070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MOG.0000000000000022","article-title":"Epidemiology of human noroviruses and updates on vaccine development","volume":"30","author":"Ramani","year":"2014","journal-title":"Curr Opin Gastroenterol"},{"issue":"2","key":"10.1016\/j.vaccine.2017.06.043_b0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12560-014-9145-5","article-title":"Norovirus outbreaks on commercial cruise ships: a systematic review and new targets for the public health agenda","volume":"6","author":"Bert","year":"2014","journal-title":"Food Environ Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2017.06.043_b0080","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/cid\/cis372","article-title":"Severe outcomes are associated with genogroup 2 genotype 4 norovirus outbreaks: a systematic literature review","volume":"55","author":"Desai","year":"2012","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2017.06.043_b0085","doi-asserted-by":"crossref","unstructured":"He Y, Jin M, Chen K, Zhang H, Yang H, Zhuo F, et al. Gastroenteritis outbreaks associated with the emergence of the new GII.4 Sydney norovirus variant during the epidemic of 2012\/13 in Shenzhen City, China. PLOS ONE 2016;11(11):e0165880 [Iturriza-G\u00f3mara M, editor].","DOI":"10.1371\/journal.pone.0165880"},{"issue":"12","key":"10.1016\/j.vaccine.2017.06.043_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6412a1","article-title":"Outbreaks of acute gastroenteritis transmitted by person-to-person contact, environmental contamination, and unknown modes of transmission\u2014United States, 2009\u20132013","volume":"64","author":"Wikswo","year":"2015","journal-title":"MMWR Surveill Summ"},{"issue":"3","key":"10.1016\/j.vaccine.2017.06.043_b0095","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/INF.0000000000000546","article-title":"The burden of norovirus disease in children in the European Union","volume":"34","author":"Kowalzik","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"10.1016\/j.vaccine.2017.06.043_b0100","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1473-3099(14)70767-4","article-title":"Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis","volume":"14","author":"Ahmed","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2017.06.043_b0105","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/INF.0b013e3181a4bb60","article-title":"Symptomatic and asymptomatic rotavirus and norovirus infections during infancy in a Chilean birth cohort","volume":"28","author":"O\u2019Ryan","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2017.06.043_b0110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/INF.0000000000001369","article-title":"Norovirus in Latin America: systematic review and meta-analysis","volume":"36","author":"O\u2019Ryan","year":"2017","journal-title":"Pediatr Infect Dis J"},{"issue":"10051","key":"10.1016\/j.vaccine.2017.06.043_b0115","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0140-6736(16)31529-X","article-title":"Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study","volume":"388","author":"Liu","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2017.06.043_b0120","unstructured":"Moyo SJ, Gro N, Matee MI, Kitundu J, Myrmel H, Mylvaganam H, et al. Age specific aetiological agents of diarrhoea in hospitalized children aged less than five years in Dar es Salaam, Tanzania. BMC Pediatr; 2011;11(1) [Internet]. Available from: http:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/1471-2431-11-19 [cited 2017 Jan 23]."},{"issue":"11","key":"10.1016\/j.vaccine.2017.06.043_b0125","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1097\/INF.0000000000000427","article-title":"Etiology of childhood diarrhea after rotavirus vaccine introduction: a prospective, population-based study in Nicaragua","volume":"33","author":"Becker-Dreps","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"10.1016\/j.vaccine.2017.06.043_b0130","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/INF.0000000000001305","article-title":"Decrease of rotavirus gastroenteritis to a low level without resurgence for five years after universal RotaTeq vaccination in Finland","volume":"35","author":"Hemming-Harlo","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"88","key":"10.1016\/j.vaccine.2017.06.043_b0135","first-page":"33","article-title":"Acute norovirus gastroenteritis in children in a highly rotavirus-vaccinated population in Northeast Brazil","volume":"29","author":"Santos","year":"2016","journal-title":"J Clin Virol Off Publ Pan Am Soc Clin Virol"},{"key":"10.1016\/j.vaccine.2017.06.043_b0140","doi-asserted-by":"crossref","unstructured":"Chau ML, Hartantyo SHP, Yap M, Kang JSL, Aung KT, Guti\u00e9rrez RA, et al. Diarrheagenic pathogens in adults attending a hospital in Singapore. BMC Infect Dis 2015;16(1) [Internet]. Available from: http:\/\/www.biomedcentral.com\/1471-2334\/16\/32 [cited 2017 Jan 23].","DOI":"10.1186\/s12879-016-1354-0"},{"issue":"suppl 1","key":"10.1016\/j.vaccine.2017.06.043_b0145","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/infdis\/jiv411","article-title":"Age-specific incidence rates for norovirus in the community and presenting to primary healthcare facilities in the United Kingdom","volume":"213","author":"O\u2019Brien","year":"2016","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2017.06.043_b0150","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/jmv.24436","article-title":"Molecular epidemiology of norovirus in children and the elderly in Atlanta, Georgia, United States: norovirus in children and elderly","volume":"88","author":"Yi","year":"2016","journal-title":"J Med Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2017.06.043_b0155","doi-asserted-by":"crossref","first-page":"ofw169","DOI":"10.1093\/ofid\/ofw169","article-title":"Epidemiology of Norovirus Infection Among Immunocompromised Patients at a Tertiary Care Research Hospital, 2010\u20132013","volume":"3","author":"Bok","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"22","key":"10.1016\/j.vaccine.2017.06.043_b0160","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMra1207742","article-title":"Norovirus gastroenteritis in immunocompromised patients","volume":"367","author":"Bok","year":"2012","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.vaccine.2017.06.043_b0165","doi-asserted-by":"crossref","first-page":"8048","DOI":"10.1073\/pnas.0600421103","article-title":"X-ray structure of a native calicivirus: structural insights into antigenic diversity and host specificity","volume":"103","author":"Chen","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5438","key":"10.1016\/j.vaccine.2017.06.043_b0170","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1126\/science.286.5438.287","article-title":"X-ray crystallographic structure of the Norwalk virus capsid","volume":"286","author":"Prasad","year":"1999","journal-title":"Science"},{"issue":"40","key":"10.1016\/j.vaccine.2017.06.043_b0175","doi-asserted-by":"crossref","first-page":"E5830","DOI":"10.1073\/pnas.1609990113","article-title":"Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody","volume":"113","author":"Shanker","year":"2016","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2017.06.043_b0180","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1006\/viro.1993.1345","article-title":"Sequence and genomic organization of Norwalk virus","volume":"195","author":"Jiang","year":"1993","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2017.06.043_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.femsle.2005.08.031","article-title":"Norovirus protein structure and function","volume":"253","author":"Hardy","year":"2005","journal-title":"FEMS Microbiol Lett"},{"issue":"6","key":"10.1016\/j.vaccine.2017.06.043_b0190","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1128\/JCM.01890-05","article-title":"Novel recombinant norovirus causing outbreaks of gastroenteritis in Santiago, Chile","volume":"44","author":"Vidal","year":"2006","journal-title":"J Clin Microbiol"},{"issue":"Pt 4","key":"10.1016\/j.vaccine.2017.06.043_b0195","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1099\/vir.0.81532-0","article-title":"Genetic and antigenic diversity among noroviruses","volume":"87","author":"Hansman","year":"2006","journal-title":"J Gen Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2017.06.043_b0200","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s00705-015-2545-5","article-title":"Human norovirus genogroup II recombinants in Thailand, 2009\u20132014","volume":"160","author":"Phumpholsup","year":"2015","journal-title":"Arch Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.06.043_b0205","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12560-012-9092-y","article-title":"Molecular detection and genotyping of noroviruses","volume":"4","author":"Stals","year":"2012","journal-title":"Food Environ Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2017.06.043_b0210","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1086\/605127","article-title":"Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001\u20132007","volume":"200","author":"Siebenga","year":"2009","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2017.06.043_b0215","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jcv.2012.11.011","article-title":"Molecular epidemiology of noroviruses associated with acute sporadic gastroenteritis in children: Global distribution of genogroups, genotypes and GII.4 variants","volume":"56","author":"Hoa Tran","year":"2013","journal-title":"J Clin Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2017.06.043_b0220","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00705-013-1806-4","article-title":"Failure of propagation of human norovirus in intestinal epithelial cells with microvilli grown in three-dimensional cultures","volume":"159","author":"Takanashi","year":"2014","journal-title":"Arch Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2017.06.043_b0225","doi-asserted-by":"crossref","first-page":"e1001807","DOI":"10.1371\/journal.pmed.1001807","article-title":"Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial","volume":"12","author":"Lindesmith","year":"2015","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.vaccine.2017.06.043_b0230","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1128\/CVI.00516-14","article-title":"Experimental human infection with Norwalk virus elicits a surrogate neutralizing antibody response with cross-genogroup activity","volume":"22","author":"Czak\u00f3","year":"2015","journal-title":"Clin Vaccine Immunol CVI"},{"issue":"5","key":"10.1016\/j.vaccine.2017.06.043_b0235","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm860","article-title":"Human susceptibility and resistance to Norwalk virus infection","volume":"9","author":"Lindesmith","year":"2003","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.vaccine.2017.06.043_b0240","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1128\/IAI.37.2.463-468.1982","article-title":"Immunoglobulin M responses to the Norwalk virus of gastroenteritis","volume":"37","author":"Cukor","year":"1982","journal-title":"Infect Immun."},{"issue":"2","key":"10.1016\/j.vaccine.2017.06.043_b0245","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJM197707142970204","article-title":"Clinical immunity in acute gastroenteritis caused by Norwalk agent","volume":"297","author":"Parrino","year":"1977","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.vaccine.2017.06.043_b0250","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/jmv.21237","article-title":"Norwalk virus: how infectious is it?","volume":"80","author":"Teunis","year":"2008","journal-title":"J Med Virol."},{"issue":"4","key":"10.1016\/j.vaccine.2017.06.043_b0255","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/cid\/cit763","article-title":"Multiple norovirus infections in a birth cohort in a Peruvian Periurban community","volume":"58","author":"Saito","year":"2014","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"10","key":"10.1016\/j.vaccine.2017.06.043_b0260","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/cid\/ciw072","article-title":"Norovirus infection and acquired immunity in 8 countries: results from the MAL-ED study","volume":"62","author":"Rouhani","year":"2016","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"11","key":"10.1016\/j.vaccine.2017.06.043_b0265","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/infdis\/jiu672","article-title":"Norovirus infection and disease in an Ecuadorian birth cohort: association of certain norovirus genotypes with host FUT2 secretor status","volume":"211","author":"Lopman","year":"2015","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2017.06.043_b0270","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1128\/JVI.79.5.2900-2909.2005","article-title":"Cellular and humoral immunity following Snow Mountain virus challenge","volume":"79","author":"Lindesmith","year":"2005","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2017.06.043_b0275","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/infdis\/161.1.18","article-title":"Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults","volume":"161","author":"Johnson","year":"1990","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2017.06.043_b0280","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/cid\/civ165","article-title":"Innate susceptibility to Norovirus infections influenced by FUT2 genotype in a United States pediatric population","volume":"60","author":"Currier","year":"2015","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"1","key":"10.1016\/j.vaccine.2017.06.043_b0285","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/jmv.20423","article-title":"Norwalk virus infection associates with secretor status genotyped from sera","volume":"77","author":"Hutson","year":"2005","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2017.06.043_b0290","doi-asserted-by":"crossref","unstructured":"Davenport ER, Goodrich JK, Bell JT, Spector TD, Ley RE, Clark AG. ABO antigen and secretor statuses are not associated with gut microbiota composition in 1500 twins. BMC Genomics 2016;17(1) [Internet]. Available from: http:\/\/bmcgenomics.biomedcentral.com\/articles\/10.1186\/s12864-016-3290-1 [cited 2017 May 24].","DOI":"10.1186\/s12864-016-3290-1"},{"issue":"11","key":"10.1016\/j.vaccine.2017.06.043_b0295","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1001\/jamapediatrics.2015.2002","article-title":"Epidemiologic association between FUT2 secretor status and severe rotavirus gastroenteritis in children in the United States","volume":"169","author":"Payne","year":"2015","journal-title":"JAMA Pediatr"},{"issue":"4","key":"10.1016\/j.vaccine.2017.06.043_b0300","doi-asserted-by":"crossref","first-page":"e1005334","DOI":"10.1371\/journal.ppat.1005334","article-title":"Correlates of protection against norovirus infection and disease-where are we now, where do we go?","volume":"12","author":"Ramani","year":"2016","journal-title":"PLoS Pathog"},{"issue":"23","key":"10.1016\/j.vaccine.2017.06.043_b0305","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa1101245","article-title":"Norovirus vaccine against experimental human Norwalk Virus illness","volume":"365","author":"Atmar","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2017.06.043_b0310","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/infdis\/jiu497","article-title":"Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults","volume":"211","author":"Bernstein","year":"2015","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2017.06.043_b0315","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0016-5085(99)70548-2","article-title":"Recombinant Norwalk virus-like particles given orally to volunteers: phase I study","volume":"117","author":"Ball","year":"1999","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.vaccine.2017.06.043_b0320","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/315653","article-title":"Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes","volume":"182","author":"Tacket","year":"2000","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2017.06.043_b0325","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1086\/657087","article-title":"Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues","volume":"202","author":"El-Kamary","year":"2010","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2017.06.043_b0330","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.clim.2012.05.006","article-title":"Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers","volume":"144","author":"Ramirez","year":"2012","journal-title":"Clin Immunol Orlando Fla"},{"issue":"11","key":"10.1016\/j.vaccine.2017.06.043_b0335","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/infdis\/jiu337","article-title":"A novel intramuscular bivalent norovirus virus-like particle vaccine candidate\u2013reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults","volume":"210","author":"Treanor","year":"2014","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2017.06.043_b0340","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.vaccine.2014.09.073","article-title":"Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine","volume":"33","author":"Sundararajan","year":"2015","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2017.06.043_b0345","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.vaccine.2016.01.064","article-title":"Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulation","volume":"34","author":"Springer","year":"2016","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2017.06.043_b0350","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1016\/j.vaccine.2012.03.050","article-title":"Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations","volume":"30","author":"Parra","year":"2012","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2017.06.043_b0355","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/infdis\/jiw259","article-title":"Rapid responses to 2 virus-like particle norovirus vaccine candidate formulations in healthy adults: a randomized controlled trial","volume":"214","author":"Atmar","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.06.043_b0360","doi-asserted-by":"crossref","first-page":"9171632","DOI":"10.1155\/2016\/9171632","article-title":"Rotavirus recombinant VP6 nanotubes act as an immunomodulator and delivery vehicle for norovirus virus-like particles","volume":"2016","author":"Malm","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.vaccine.2017.06.043_b0365","doi-asserted-by":"crossref","unstructured":"Tamminen K, Lappalainen S, Huhti L, Vesikari T, Blazevic V. Trivalent Combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS ONE 2013;8(7):e70409 [Zhou P, editor].","DOI":"10.1371\/journal.pone.0070409"},{"issue":"43","key":"10.1016\/j.vaccine.2017.06.043_b0370","doi-asserted-by":"crossref","first-page":"5779","DOI":"10.1016\/j.vaccine.2015.09.043","article-title":"A bivalent virus-like particle based vaccine induces a balanced antibody response against both enterovirus 71 and norovirus in mice","volume":"33","author":"Wang","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2017.06.043_b0375","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1128\/JVI.01835-10","article-title":"Norovirus P particle, a novel platform for vaccine development and antibody production","volume":"85","author":"Tan","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.06.043_b0380","doi-asserted-by":"crossref","unstructured":"Fang H, Tan M, Xia M, Wang L, Jiang X. Norovirus P Particle Efficiently elicits innate, humoral and cellular immunity. PLoS ONE 2013;8(4):e63269 [Bansal GP, editor].","DOI":"10.1371\/journal.pone.0063269"},{"issue":"44","key":"10.1016\/j.vaccine.2017.06.043_b0385","doi-asserted-by":"crossref","first-page":"7670","DOI":"10.1016\/j.vaccine.2011.07.139","article-title":"A candidate dual vaccine against influenza and noroviruses","volume":"29","author":"Xia","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2017.06.043_b0390","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.vaccine.2013.11.064","article-title":"A dual vaccine candidate against norovirus and hepatitis E virus","volume":"32","author":"Wang","year":"2014","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2017.06.043_b0395","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.vaccine.2015.12.068","article-title":"A trivalent vaccine candidate against hepatitis E virus, norovirus, and astrovirus","volume":"34","author":"Xia","year":"2016","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2017.06.043_b0400","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12967-016-0899-4","article-title":"Norovirus (NoV) specific protective immune responses induced by recombinant P dimer vaccine are enhanced by the mucosal adjuvant FlaB","volume":"14","author":"Verma","year":"2016","journal-title":"J Transl Med"},{"issue":"6","key":"10.1016\/j.vaccine.2017.06.043_b0405","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1128\/JVI.02332-10","article-title":"Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus","volume":"85","author":"Ma","year":"2011","journal-title":"J Virol"},{"issue":"17","key":"10.1016\/j.vaccine.2017.06.043_b0410","doi-asserted-by":"crossref","first-page":"9718","DOI":"10.1128\/JVI.01570-14","article-title":"Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice","volume":"88","author":"Kim","year":"2014","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2017.06.043_b0415","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1128\/JVI.76.6.3023-3030.2002","article-title":"Expression and self-assembly of Norwalk virus capsid protein from venezuelan equine encephalitis virus replicons","volume":"76","author":"Baric","year":"2002","journal-title":"J Virol."},{"issue":"7","key":"10.1016\/j.vaccine.2017.06.043_b0420","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1128\/JVI.01650-08","article-title":"Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge","volume":"83","author":"LoBue","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.06.043_b0425","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cbpa.2016.03.001","article-title":"Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine","volume":"32","author":"Bryan","year":"2016","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.vaccine.2017.06.043_b0430","doi-asserted-by":"crossref","unstructured":"Groome MJ, Koen A, Fix A, Page N, Jose L, Madhi SA, et al. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2017 [Internet]. Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473309917302426 [cited 2017 May 25].","DOI":"10.1016\/S1473-3099(17)30242-6"},{"key":"10.1016\/j.vaccine.2017.06.043_b0435","unstructured":"O\u2019Ryan M, Lopman BA. Parenteral protein-based rotavirus vaccine. Lancet Infect Dis 2017 May [Internet]. Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147330991730244X [cited 2017 May 25]."},{"issue":"12","key":"10.1016\/j.vaccine.2017.06.043_b0440","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/nprot.2015.121","article-title":"Human norovirus culture in B cells","volume":"10","author":"Jones","year":"2015","journal-title":"Nat Protoc"},{"key":"10.1016\/j.vaccine.2017.06.043_b0445","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.antiviral.2016.05.011","article-title":"Inhibition of human norovirus by a viral polymerase inhibitor in the B cell culture system and in the mouse model","volume":"132","author":"Kolawole","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2017.06.043_b0450","doi-asserted-by":"crossref","unstructured":"Qu L, Murakami K, Broughman JR, Lay MK, Guix S, Tenge VR, et al. Replication of human norovirus RNA in mammalian cells reveals lack of interferon response. J Virol 2016;90(19):8906\u201323 [L\u00f3pez S, editor].","DOI":"10.1128\/JVI.01425-16"},{"key":"10.1016\/j.vaccine.2017.06.043_b0455","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.molimm.2016.08.009","article-title":"Type-specific and cross-reactive antibodies and T cell responses in norovirus VLP immunized mice are targeted both to conserved and variable domains of capsid VP1 protein","volume":"78","author":"Malm","year":"2016","journal-title":"Mol Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2017.06.043_b0460","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1080\/21645515.2015.1099772","article-title":"Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine","volume":"12","author":"Blazevic","year":"2016","journal-title":"Hum Vaccines Immunother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17308307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17308307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T05:29:44Z","timestamp":1750397384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17308307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":92,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0264410X17308307"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.06.043","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Norovirus vaccines under development","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.06.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}